A Phase 2/3 interventional study of MP-214 in Schizophrenia, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Tanabe Pharma Corporation · Phase 2/3, Interventional, and Treatment
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 42 is below the median of 70 across 2,872 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Tanabe Pharma Corporation is the lead sponsor of 91 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Drug: MP-214
Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame: Up to 60 weeks
| Milestone | MP-214 1.5-9 mg |
|---|---|
| Started | 42 |
| Completed | 30 |
| Not completed | 12 |
| Withdrew: Adverse event | 8 |
| Withdrew: Withdrawal by subject | 4 |
| Participants | MP-214 1.5-9 mg |
|---|---|
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 42 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MP-214 1.5-9 mg | — | 2/42 (4.8%) | 37/42 (88.1%) |
| Event | MP-214 1.5-9 mg |
|---|---|
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 1/42 |
| SchizophreniaPsychiatric disorders | 1/42 |
| Event | MP-214 1.5-9 mg |
|---|---|
| NasopharyngitisInfections and infestations | 18/42 |
| SchizophreniaPsychiatric disorders | 8/42 |
| HeadacheNervous system disorders | 7/42 |
| SomnolenceNervous system disorders | 7/42 |
| Blood creatine phosphokinase increasedInvestigations | 6/42 |
| Weight increasedInvestigations | 6/42 |
| Extrapyramidal disorderNervous system disorders | 6/42 |
| Alanine aminotransferase increasedInvestigations | 5/42 |
| InsomniaPsychiatric disorders | 5/42 |
| NauseaGastrointestinal disorders | 4/42 |
| Age, Continuous(years) | MP-214 1.5-9 mg |
|---|---|
| Mean | 40.4 ± 10.7 |
| Sex: Female, Male(Participants) | MP-214 1.5-9 mg |
|---|---|
| Female | 19 |
| Male | 23 |
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tanabe Pharma Corporation